

INVESTIGATING NEUROPATHOLOGICAL CORRELATES OF HYPERACTIVE AND PSYCHOTIC SYMPTOMS IN DEMENTIA, A SYSTEMATIC REVIEW

A. GATTI, G. NEGRO, C. IMBIMBO, A. MAGI, C. CALATOZZOLO, M. ROSSI, A. COSTA, TINO EMANUELE POLONI.

INTRO

Neuropsychiatric symptoms frequently complicate the phases of cognitive worsening of dementia. They are defined as: behavioral-psychological symptoms of dementia or BPSD. In this spectrum, the HIDA-P cluster is difficult to manage and severely impacts caregiving. Pathophysiology and neuropathology underlying HIDA-P remain poorly understood.

AIMS

To clarify what is known about the neuropathology of the HIDA-P cluster, to elucidate whether different proteinopathies are associated with peculiar symptoms and which are the neural circuits associated with these symptoms

HOW?


PRISMA guidelines, with a systematic search across MEDLINE, CENTRAL, and EMBASE databases.

37 OUT OF 846 ARTICLES MET INCLUSION CRITERIA FOR A TOTAL OF 18823 CASES:

Clinical Diagnosis	% of cohort	HIDA-P symptom	Prevalence %
Alzheimer's disease	83%	Agitation / aggression	14
Frontotemporal dementia	13%	Delusions	11,6
Dementia with Lewy bodies	5%	Disinhibition	7,61
—	—	Hallucinations	6,83
—	—	Irritability	7
—	—	Aberrant motor	5,4



Lesion / pathology	Agitation / Aggression	Disinhibition	Delusions	Hallucinations
Tau (ADNC, Braak III-VI)	+++	+++	+++	+++
α-Synuclein (Lewy bodies)	++	+	++	++
TDP-43 (LATE-NC)	++	+	+	+
Mixed (Tau + α-syn ± TDP-43)	++++	++++	++++	++++
Vascular / CAA	- / ±	-	±	±



TAKE HOME MESSAGE

- TOPOGRAPHY WINS OVER CHEMISTRY – LESION LOCATION AND BURDEN, NOT SPECIFIC PROTEINOPATHIES, DICTATE HIDA-P BEHAVIOURS.
- AMYGDALA-CENTRIC LIMBIC DYSFUNCTION – TAUOPATHY AND COMBINED PROTEINOPATHIES INTO THE AMYGDALA AND THE LIMBIC SYSTEM REPRESENT THE MORE FREQUENT NEUROPATHOLOGY RELATED TO THE HIDA-P CLUSTER
- MIXED PROTEINOPATHIES (TAU + A-SYNUCLEIN ± TDP-43) AMPLIFY SYMPTOM SEVERITY – MULTITARGET THERAPIES REQUIRED.
- NO BEHAVIOUR IS PATHOGNOMONIC – HALLUCINATIONS, DISINHIBITION AND AGGRESSION OCCUR ACROSS ALZHEIMER, FTD, DLB AND MIXED CASES.

SOME REFLECTIONS

- SHIFT FROM PROTEIN-NAMED DIAGNOSES TO CIRCUIT-BASED STAGING THAT MAPS LIMBIC-FRONTAL NETWORK DAMAGE.
- DEPLOY LIMBIC-TARGETED TAU-PET AND EMERGING A-SYNUCLEIN PET AS RISK-STRATIFIERS AND TRIAL BIOMARKERS.
- TEST COMBINATION DISEASE-MODIFYING STRATEGIES (ANTI-TAU + ANTI-SYN) TO CURB DISRUPTIVE BEHAVIOURS.
- USE HIGH-RESOLUTION DIGITAL PHENOTYPING (WEARABLES, IN-HOME SENSORS) TO REFINE CLINICOPATHOLOGICAL CORRELATIONS.
- EXPAND COHORTS TO VASCULAR DEMENTIA, UNDER-REPRESENTED ETHNICITIES AND PRODROMAL (MBI) STAGES FOR TRUE GENERALISABILITY.
- INTEGRATE NEURO-IMMUNE INDICES (MICROGLIAL ACTIVATION, ASTROCYTIC REACTIVITY) WITH PROTEINOPATHY STAGING TO UNCOVER NEW TARGETS.

AUTHORS CONTACTS

FUNDINGS: FONDO DI BENEFICENZA INTESA SANPAOLO – B 2024/0214

DOCT. TINO EMANUELE POLONI
TEPOLONI@GMAIL.COM
DEPARTMENT OF NEUROLOGY AND NEUROPATHOLOGY, GOLGI-CENCI FOUNDATION, ABBIATEGRASSO, MILAN, ITALY

DOCT.SSA GIULIA NEGRO
G.NEGRO4@CAMPUS.UNIMI.B.IT
GOLGI CENCI FOUNDATION
FONDAZIONE IRCCS SAN GERARDO DEI TINTORI, SAN GERARDO HOSPITAL, MONZA, ITALY

DOCT. ALBERTO GATTI
ALBERTO.GATTI07@UNIVERSITADIPAVIA.IT
MONDINO FOUNDATION, DEPARTMENT OF BRAIN AND BEHAVIORAL SCIENCES, UNIVERSITY OF PAVIA, PAVIA, ITALY
GOLGI CENCI FOUNDATION

PROF. ALFREDO COSTA
UNIT OF BEHAVIORAL NEUROLOGY AND CENTER FOR COGNITIVE DISORDERS AND DEMENTIA (CDD), IRCCS MONDINO FOUNDATION, PAVIA, ITALY
A.COSTA@MONDINO.IT

DOCT. MICHELE ROSSI
GOLGI CENCI FOUNDATION
M.ROSSI@GOLGICENCI.IT
DOCT. CAMILLO IMBIMBO
DEPARTMENT OF BRAIN AND BEHAVIORAL SCIENCES, UNIVERSITY OF PAVIA, PAVIA, ITALY
CAMILLO.IMBIMBO01@UNIVERSITADIPAVIA.IT

DOCT. ANDREA MAGI
NEUROLOGY DEPARTMENT, FONDAZIONE IRCCS SAN GERARDO DEI TINTORI, SAN GERARDO HOSPITAL, MONZA, ITALY
A.MAGI1@CAMPUS.UNIMI.B.IT
DOCT.SSA CHIARA CALATOZZOLO
GOLGI CENCI FOUNDATION
C.CALATOZZOLO@GOLGICENCI.IT